Pharmacokinetic drug interactions with nevirapine

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Back, David ^a   Gibbons, Sara ^a   Khoo, Saye ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Drug interactions; Nevirapine; Pharmacokinetics

Indexed keywords

AMPRENAVIR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CLOFIBRATE; CYTOCHROME P450; EFAVIRENZ; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOPINAVIR; METHADONE; MEVINOLIN; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PRAVASTATIN; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; SIMVASTATIN; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNINDEXED DRUG;

AREA UNDER THE CURVE; BIOAVAILABILITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BINDING; STEADY STATE; TREATMENT OUTCOME; TREATMENT PLANNING;

DRUG INTERACTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MEDICINE, HERBAL; METHADONE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0141681336     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00003     Document Type: Conference Paper

References (42)

1. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304.
2. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-996.
3. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-1292.
4. Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999;27:1488-1495.
5. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001;40:893-905.
6. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-291.
7. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194.
8. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41:898-905.
9. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-116.
10. Pai VB and Nahata MC. Nelfinavir mesylate: A protease inhibitor. Ann Pharmacother 1999;33:325-339.
11. Murphy RL, Sommadossi JP, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999;179:1116-1123.
12. Adkins JC, Noble S. Efavirenz. Drugs 1998;56:1055-1064.
13. von Moltke LL, Greenblatt DJ, Grande BW, et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001;41:85-91.
14. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-1023.
15. Ekins S, Erickson JA. A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 2002;30:96-99.
16. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-14587.
17. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-259.
18. Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999;62:25-31.
19. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter p-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1999;19:203-209.
20. Profit L, Eagling VA, Back DJ. Modulation of p-glycoprotein function in human lymphocytes and caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999;13:1623-1627.
21. Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir (SQV) and nevirapine (NVP) [abstract 496.] 4th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, February 1997.
22. Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998;12:1243-1244.
23. Moreno A, Casado JL, Marti-Belde P, et al. Concomitant use of non-nucleoside reverse transcriptase inhibitors (NNRTI) does not decrease the inhibitory quotient of dual ritonavir/indinavir-based therapy. Abstract 1728. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., December 2001.
24. Choudey N, Goujard C, Maeynard JL, et al. Importance of NNRTIs on the pharmacokinetics of amprenavir (APV) and ritonavir (RTV) in HIV-infected patients Abstract 1.12. Presented at the 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Nordwijk, The Netherlands, April 2001.
25. Boehringer Ingelheim International. Viramune Summary of Product Characteristics, 2001.
26. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.
27. Hsu A, Bertz R, Reiz C, et al. Assessment of pharmacokinetic interactions between kaletra (lopinavir/ritonavir or ABT-378/r) and nevirapine in paediatric subjects. AIDS 2000;14 Suppl 4:S100.
28. Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001;184:37-42.
29. Clarke SM, Mulcahy F, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001;33:1595-1597.
30. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
31. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32:403-425.
32. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45:3445-3450.
33. Ramachandran V, Kostrubsky VE, Komoroski BJ, et al. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab Dispos 1999;27:1194-1199.
34. Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991;34:1838-1844.
35. Pichard L, Gillett G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450 IIIA as the major enzymes involved in the n-demethylation of diltiazem. Drug Metab Dispos 1990;18:711-719.
36. de Maat MMR, Mathof R, Hoetelmans R, et al. A population pharmacokinetic model of nevirapine reveals drug interaction with St John's Wort in a cohort of HIV-1 infected patients. Abstract 1.2. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Nordwijk, The Netherlands, April, 2001.
37. Robinson P, Lamson M, Gigliotti M. Pharmacokinetic interaction between nevirapine and rifampin. [abstract 60623.] 12th World AIDS Conference, Durban, South Africa, July, 1998.
38. Maldonado S, Lamson M, Gigliotti M, et al. Pharmacokinetic interaction between nevirapine and rifabutin. [abstract 341.] 39th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, September, 1999.
39. Robinson P, Gigliotti M, Lamson M, et al: Effect of the reverse transcriptase inhibitor, nevaripine, on the steady state pharmacokinetics of clarithromycin in HIV positive patients. [abstract 374.] 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, January, 1999.
40. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: Current status and future directions. AIDS 2002;16 (suppl 1):S1-S35.
41. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial. Italy, The Netherlands, Canada and Australia study. JAMA 1998;279:930-937.
42. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15:1089-1095.